Literature DB >> 11391684

Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.

L Collette1, U E Studer, F H Schröder, L J Denis, R J Sylvester.   

Abstract

BACKGROUND: The meta-analysis of maximal androgen blockade (MAB) concluded that there is no survival advantage of MAB over castration alone. However, the results from the largest trials yield conflicting results.
METHODS: The design and results of three trials were examined.
RESULTS: Most studies were planned to detect an over-optimistic difference in survival and immature data were published. The survival curves show that statistical assumptions are not fulfilled. Excluding from the meta-analysis all trials where a negative impact of disease flare on survival could not be excluded resulted in no difference in survival between MAB and castration.
CONCLUSIONS: Trials of MAB should be planned to detect differences of no more than 5-10% in median survival. The analyses should only be carried out on mature data and should take into account the possibility of a negative impact on survival due to disease flare if no anti-androgen has been given initially with an LH-RH agonist. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391684     DOI: 10.1002/pros.1078

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.

Authors:  Yoshifumi Kadono; Takahiro Nohara; Satoru Ueno; Kouji Izumi; Yasuhide Kitagawa; Hiroyuki Konaka; Atsushi Mizokami; Mizuki Onozawa; Shiro Hinotsu; Hideyuki Akaza; Mikio Namiki
Journal:  World J Urol       Date:  2015-06-06       Impact factor: 4.226

2.  Expanding the use of abiraterone in prostate cancer: Is earlier always better?

Authors:  Keith T Schmidt; Ravi A Madan; William D Figg
Journal:  Cancer Biol Ther       Date:  2017-12-08       Impact factor: 4.742

Review 3.  Contemporary role of androgen deprivation therapy for prostate cancer.

Authors:  Vincenzo Pagliarulo; Sergio Bracarda; Mario A Eisenberger; Nicolas Mottet; Fritz H Schröder; Cora N Sternberg; Urs E Studer
Journal:  Eur Urol       Date:  2011-08-19       Impact factor: 20.096

Review 4.  [Androgen deprivation for advanced prostate cancer].

Authors:  A Heidenreich; D Pfister; C H Ohlmann; U H Engelmann
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

5.  Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials.

Authors:  Peter Iversen; Jan-Erik Damber; Anders Malmberg; Bo-Eric Persson; Laurence Klotz
Journal:  Ther Adv Urol       Date:  2015-12-16

Review 6.  [Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel].

Authors:  C Thomas; M Bögemann; F König; S Machtens; M Schostak; T Steuber; A Heidenreich
Journal:  Urologe A       Date:  2016-06       Impact factor: 0.639

7.  Saudi Oncology Society clinical management guidelines for prostate cancer.

Authors:  Ashraf J Abusamra; Shouki Bazarbashi; Yasser Bahader; Hussain Kushi; Danny Rabah; Dany Rabbah; Naser Al Bogami; Khalid Al Ghamdi; Abdullah Al Ghamdi; Khaled Balaraj; Raouf Seyam; Mohammed Al Otaibi; Eyad Al Saeed
Journal:  Urol Ann       Date:  2011-03

8.  Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Authors:  Sultan Alkhateeb; Ashraf Abusamra; Danny Rabah; Mohammed Alotaibi; Rana Mahmood; Mubarak Almansour; Esam Murshid; Abdullah Alsharm; Ashwaq Alolayan; Imran Ahmad; Hussain Alkushi; Abdullah Alghamdi; Shouki Bazarbashi
Journal:  Urol Ann       Date:  2014-10

9.  Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.

Authors:  H Lukka; T Waldron; L Klotz; E Winquist; J Trachtenberg
Journal:  Curr Oncol       Date:  2006-06       Impact factor: 3.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.